Independent pharmacies in Illinois are valued at 1x to 2x annual gross profit or 3x to 5x EBITDA. Script volume, average reimbursement rates, DIR fee exposure, and front-end gross margin all factor into the final valuation. The pharmacy industry has been under margin pressure from PBM practices, making profitable independents with stable cash flow increasingly rare and valuable.
Script Count and Reimbursement
Total prescriptions dispensed per year, average days supply, generic fill rate, and specialty drug volume all drive revenue. Reimbursement quality varies dramatically by payer — DIR fees imposed by PBMs can represent 3–8% of prescription revenue and must be included in net revenue calculations for accurate cash flow modeling.
Compounding and Specialty Services
Pharmacies with compounding capabilities, specialty drug dispensing licenses (for oncology, HIV, or immunology medications), or MTM (medication therapy management) programs generate higher gross margins and are more defensible against chain pharmacy competition. These differentiators command meaningful valuation premiums.
Illinois pharmacy sales require DEA registration transfer, state pharmacy license transfer, and notification to all PBMs. The HIPAA-compliant transfer of prescription records requires specific patient notification procedures. Planning this regulatory pathway early is essential to completing a smooth closing.